Affiliation: | 1. Leviev Heart Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel;2. Vascular Surgery Department, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel |
Abstract: | PurposeTo report long-term results of iliofemoral stent placement after transcatheter aortic valve replacement (TAVR).Materials and MethodsTAVR access-related complications treated with iliofemoral stent placement were recorded in 56 patients (mean age, 81 years; range; 53–93 years; 48% male) of 648 patients who underwent TAVR at a single center. Fifty-six patients treated with stent placement (40 patients with stent grafts and 16 patients with bare metal stents) underwent clinical and ultrasonographic follow-up after a mean of 676 days (range, 60–1840 days).ResultsDuring follow-up, none of the 56 patients who had stent placement underwent a vascular reintervention of the affected limb, and none suffered from limb claudication. No decrease was observed in ankle-brachial index (ABI) values to an abnormal value, except in 1 patient (mean preprocedural and postprocedural ABI of 1.2 ± 0.14, range, 0.97–1.4 and 1.19 ± 0.24, range, 0.65–1.54, respectively). Arterial duplex assessment showed normal stent flow velocity (mean, 168.7 ± 63.2 cm/sec; range, 80–345 cm/sec) in all but 1 patient.ConclusionIliofemoral stent implantation is a safe and efficacious treatment for vascular access site and access-related complications during transfemoral TAVR. |